Abstract:
BACKGROUND/OBJECTIVE: Medullary thyroid carcinoma (MTC) is a rare yet aggressive form
of thyroid cancer comprising a disproportionate share of thyroid cancer-related mortalities, despite its
low prevalence. MTC differs from other differentiated thyroid malignancies due to its heterogeneous
nature, presenting complexities in both hereditary and sporadic cases. Traditional management
guidelines, which are designed primarily for papillary thyroid carcinoma (PTC), fall short in providing the individualized care required for patients with MTC. In recent years, the sheer volume
of data generated from clinical evaluations, radiological imaging, pathological assessments, genetic
mutations, and immunological profiles has made it humanly impossible for clinicians to simultaneously analyze and integrate these diverse data streams effectively. This data deluge necessitates
the adoption of advanced technologies to assist in decision-making processes. Holomics, which is
an integrated approach that combines various omics technologies, along with artificial intelligence
(AI), emerges as a powerful solution to address these challenges. METHODS: This article reviews
how AI-driven precision oncology can enhance the diagnostic workup, staging, risk stratification,
management, and follow-up care of patients with MTC by processing vast amounts of complex
data quickly and accurately. Articles published in English language and indexed in Pubmed were searched. RESULTS: AI algorithms can identify patterns and correlations that may not be apparent
to human clinicians, thereby improving the precision of personalized treatment plans. Moreover,
the implementation of AI in the management of MTC enables the collation and synthesis of clinical
experiences from across the globe, facilitating a more comprehensive understanding of the disease
and its treatment outcomes. CONCLUSIONS: The integration of holomics and AI in the management
of patients with MTC represents a significant advancement in precision oncology. This innovative
approach not only addresses the complexities of a rare and aggressive disease but also paves the way
for global collaboration and equitable healthcare solutions, ultimately transforming the landscape
of treatment and care of patients with MTC. By leveraging AI and holomics, we can strive toward
making personalized healthcare accessible to every individual, regardless of their economic status,
thereby improving overall survival rates and quality of life for MTC patients worldwide. This global
approach aligns with the United Nations Sustainable Development Goal 3, which aims to ensure
healthy lives and promote well-being at all ages.
